Reading MLSS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MLSS free→Reading MLSS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MLSS free→
AMEXHealth CareMedical Instruments & SuppliesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral. Earnings quality is fragile, and management is volatile. The capital stance is unfriendly to shareholders. Risk is high, and the sector backdrop is a headwind. Compared with sector peers, MLSS is typical. Peer multiples imply a price about 62% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This trades below peer multiples, but recent financials are weak or earnings quality is fragile, historically a value-trap pattern. Watch for trends in sector bellwethers like ISRG, MDLN, and BDX. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $0.34. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.34 MLSS trades at 3× p/s, in line with its 3× p/s peer median. Our $0.95 fair value reflects that, medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 64% below a flat-multiple fair value, below our forecast of about 7%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted -0.26x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates.
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.01 → $-0.01 (+0.0% / 30d). 0 raised, 0 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$287.
How much price usually moves either way.
On a bad day, this stock has moved -$896.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,200.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for MLSS yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Changes in Registrant’s Certifying Accountant On April 30, 2026, the Board of Directors of Milestone Scientific Inc. (the “Company”) approved the dismissal of CBIZ CPAs P.C. (“CBIZ CPAs”) as the independent registered public accounting firm to the Company effective as of May 15, 2026. The Company engaged Grassi & Co., CPAs, P.C. to be the independent registered public accounting firm to the Company for the fiscal year ending December 31, 2026. The approval of the dismissal of CBIZ CPAs was ap…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2022-Q2, 2022-Q3, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
MLSS Milestone Scientific Inc | Typical Show detailsSector percentile: 40 of 100 | inexpensive | high |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 78 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 94 of 100 | fair | elevated |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue strategic M&A activities with Innovest S.p.A. to enhance market position.
Stated in 2 of last 2 quarters. Milestone Scientific has been actively engaging in M&A activities with Innovest S.p.A., as evidenced by the amended MOU regarding BP4 S.r.l. This recurring focus on strategic partnerships indicates a commitment to growth, though specific financial impacts are not detailed in the current financials.
“Entry into an amended MOU with Innovest S.p.A. regarding BP4 S.r.l.”
“Entered into an Amended and Restated MOU with Innovest S.p.A.”
Focus on improving cash flow from operations to strengthen financial stability.
Stated in 2 of last 2 quarters. Cash from operations improved significantly to $86,842 in 2026-Q1 from a negative $226,129 in 2025-Q4, indicating progress in operational efficiency. This improvement aligns with management's focus on enhancing cash flow, showing a positive trajectory.
“Cash from operations improved to $86,842.”
Utilize private placements to optimize capital allocation and support growth initiatives.
Newly stated in 2026-Q1. Milestone Scientific entered into a securities purchase agreement for a private placement of 7,962,963 units, indicating a strategic move to enhance capital allocation. This initiative supports growth but lacks detailed financial impact in the current period.
“Entered into a securities purchase agreement for a private placement.”
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 30, 2026 (the “Effective Date”), the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Milestone Scientific Inc. (the “Company”) approved a one-time stock option exchange program (the “Exchange Program”) for outstanding stock options granted under the Company’s Amended and Restated 2020 Equity Incentive Pla…
Entry into a Material Definitive Agreement On April 20, 2026, Milestone Scientific Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of an aggregate of 7,962,963 units (the “Units”), with each Unit consisting of (i) one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) one warrant to purchase one share…
Unregistered Sales of Equity Securities The disclosures set forth in
Entry into a Material Definitive Agreement On March 31, 2026, Milestone Scientific Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Amended and Restated Memorandum of Understanding, dated January 13, 2026 (the “MOU”), with Innovest S.p.A., as the holder of certain consent/blockage rights with respect to BP4 S.r.l., a society’ a responsibility’ limitation in liquidation (“BP4”). According to BP4, it was then the owner of 11.31% of the outstanding shares of common stock o…
“Cash from operations was negative $226,129.”